Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Toronto-Dominion Bank — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while Toronto-Dominion Bank trades at $123.07 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 6.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TD | |
|---|---|---|
Market Cap | $29.60B | $200.48B |
Sector | Health | Financials |
52-Week High | $491.22 | $124.80 |
52-Week Low | $205.48 | $72.85 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
TD stock trades at $123.01, up 1.59% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong 2025 results with $61.28B revenue and $20.54B net income, though cash flow from operations was negative. Analyst consensus is positive with 9 buy ratings and no sell recommendations. Recent news highlights TD Auto Finance's industry recognition and AI-driven operational efficiencies.
The outlook is favorable given earnings momentum and dividend stability, but risks include volatile operating cash flows and high debt levels. Valuation metrics like P/E of 19.88 and P/B of 2.48 suggest reasonable pricing relative to peers, supporting a cautiously optimistic view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
